<DOC>
	<DOCNO>NCT00003658</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine pentostatin , cyclophosphamide , rituximab treat patient chronic lymphocytic leukemia B-cell cancer treat previously .</brief_summary>
	<brief_title>Pentostatin , Cyclophosphamide , Rituximab Treating Patients With Chronic Lymphocytic Leukemia Other B-cell Cancers</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose cyclophosphamide , filgrastim ( G-CSF ) support , safely administer pentostatin rituximab patient previously treat intermediate- high-risk chronic lymphocytic leukemia low-grade B-cell malignancy . ( Phase I close accrual effective 11/27/2001 . ) - Characterize toxicity regimen patient . - Determine incidence response patient treat regimen . OUTLINE : This multicenter , dose-escalation study cyclophosphamide ( CTX ) . - Phase I : Patients receive CTX IV follow pentostatin IV day 1 course 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 3 continue blood count recover . During second subsequent course , patient receive CTX IV , pentostatin IV , rituximab IV day 1 . Patients also receive G-CSF course 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients least partial response third course receive additional 3 course . Cohorts 3-6 patient receive escalate dos CTX maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . ( Phase I close accrual effective 11/27/2001 . ) - Phase II : Patients receive CTX recommend phase II dose treatment . Patients follow least every 3 month 1 year periodically thereafter . PROJECTED ACCRUAL : A total 3-30 patient accrued phase I portion study . ( Phase I close accrual effective 11/27/2001 . ) A total 14-30 patient accrue phase II portion study within 2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Intermediate highrisk chronic lymphocytic leukemia ( CLL ) define threestage Rai system Rai intermediate disease must active disease ( include weight loss , fatigue , fever , evidence progressive marrow failure , splenomegaly , progressive lymphadenopathy , progressive lymphocytosis rapid doubling time ) Other lowgrade Bcell neoplasms , include small lymphocytic lymphoma ( variant ) , Waldenstrom 's macroglobulinemia , follicular lymphoma allow Autoimmune hemolytic anemia autoimmune thrombocytopenia allow regardless disease stage Bcells demonstrate immunophenotypic ( immunohistochemical ) analysis malignant lymphocytes Must previously treat For CLL , absolute lymphocytosis blood least 5,000 lymphocytes/mm^3 OR Bone marrow lymphocytosis least 30 % nucleated cell No Rai intermediaterisk disease meet criteria Montserrat `` smolder leukemia '' NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 4 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Other : No active infection require systemic antibiotic Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy Concurrent intravenous immunoglobulin allow Concurrent epoetin alfa allow Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Concurrent prednisone therapy allow long dose stable decrease past 4 week No increase prednisone therapy study Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>